All In MedTech

FDA Clearance Tracker · P180031-S006

Neuroform Atlas® Stent System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 24, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P180031-S006
Device name
Neuroform Atlas® Stent System
Applicant location
Fremont, CA
Received
Aug 12, 2024
Decided
Jun 24, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P180031

Device type

Device class
Class III

Every decision under product code QCA

FDA's approval statement

As written in FDA's record.

PMA was approved on May 16, 2019 with the following conditions of approval:PMA Post-Approval Study: “Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms with the Neuroform Atlas™ Stent System (ATLAS)”: The Office of Neurological and Physical Medicine Devices (Office of Health Technology (OHT) 5) will have the lead for this study initiated prior to device approval. The ATLAS study was conducted under investigational device exemption (IDE) G150006 and patients were consented to be followed for up to three (3) years post-operative. The 1-year follow-up data from the ATLAS study was used to support the approval of the subject PMA P180031. As part of the PMA post-approval study, the long-term follow-up from the ATLAS study can provide safety and effectiveness information on the durability and safety of treatment using the Neuroform Atlas Stent System up to 3 years post-operative. The pre-specified safety endpoint is the incidence of patients who experienced a major ipsilateral stroke or neurological death. The pre-specified effectiveness endpoint is the incidence of patients who had complete (100%) intracranial aneurysm occlusion (Raymond-Roy Class 1) without significant in-stent stenosis (> 50%) or retreatment of the target aneurysm. The incidence of all ischemic or hemorrhagic adverse events (i.e., ischemic and hemorrhagic, ipsilateral and contralateral, of all severities, at all times after enrollment, and of any duration, including transient ischemic attacks (TIAs)) should also be reported as part of the long-term safety analysis. Patients will be assessed at 2- and 3-years (within ± 6 months) post-operative with neurological exams conducted in person per the G150006 clinical study protocol. In addition, all new and ongoing adverse events will be recorded and adjudicated by the Clinical Events Committee per the approved G150006 clinical study protocol. Imaging assessment of intracranial aneurysm occlusion and in-stent stenosis will be performed after 1-year post-operative if imaging assessments will be performed as part of usual care.

Source documents

Other decisions for Stryker Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.